Deals this week: Biolife Solutions, RenalSense, Biomerics

4 May 2018 (Last Updated May 4th, 2018 11:07)

Biolife Solutions Inc has raised $2.57m through the private placement of 540,896 shares of its common stock priced at $4.75 a share.

Biolife Solutions Inc has raised $2.57m through the private placement of 540,896 shares of its common stock priced at $4.75 a share.

Based in the US, Biolife Solutions is a developer, manufacturer and supplier of proprietary, clinical-grade storage and cryopreservation freeze media for cells and tissues.

RenalSense Ltd has signed a distribution agreement with Fresenius Medical Care AG and Co KGaA for its Clarity RMS critical care urine monitoring system in Europe, the Middle East, and Africa (EMEA).

Fresenius will distribute RenalSense’s products in 85 EMEA countries through its acute care division, as part of the transaction.

Based in Israel, RenalSense is a medical device company focused on real-time renal diagnostics, while Fresenius Medical Care is a Germany-based company offering dialysis and kidney disease treatments.

Biomerics LLC and ATL Technology LLC have formed a joint venture named Biomerics ATL LLC to acquire medical device manufacturer Catheter Research Inc’s (CRI) business in the Indianapolis and Costa Rica divisions.

Biomerics is a medical devices developer and producer, while ATL is an electromechanical contract manufacturing services provider.

All the companies involved in the transaction are based in the US.

US-based life science solutions developer and manufacturer Harvard Bioscience Inc plans to raise $50m through a public offering of securities.

The proceeds from the offering are intended to be used for working capital and other general corporate purposes.

Iron Bow Technologies plans to partner with Vidyo Inc with an intention to deliver a new eICU patient monitoring device.

“Iron Bow Technologies plans to partner with Vidyo Inc with an intention to deliver a new eICU patient monitoring device.”

The planned eICU product will be manufactured by Iron Bow under the brand Vidyo. It will enable clinicians to remotely monitor and assess a patient’s condition.

Based in the US, Iron Bow Technologies is an IT solutions provider, while Vidyo, also based in the US, is a provider of video collaboration and communication platform.

Wuxi Vision Pro LTD has raised $12.6m through a series B financing round led by Qiming Venture. Shanghai Ruijian Capital Management Co Ltd also participated in the funding round.

Based in China, Wuxi is a manufacturer of intraocular lenses and related products, while Qiming Venture and Shanghai Ruijian Capital Management are both venture capital firms based in China.

Eyenuk Inc has raised $3m by issuing series S-2 preferred stock to six investors.

Based in the US, Eyenuk is a diagnostic company that provides retinal image analysis technology products.

UK-based Mologic Ltd has signed an agreement with Medisur and Peripal to distribute the point-of-care (POC) diagnostic test, PERiPLEX, in European markets.

PERiPLEX is used for the detection of infection in patients on peritoneal dialysis (PD) using a lateral flow immunoassay system.

Medisur and Peripal will supply PERiPLEX as part of a complementary product portfolio in European markets, including France, Germany, Italy, the Netherlands, Austria, and Switzerland.

Based in France, Medisur is a medical technology company, while Peripal, also a medical technology company, is based in Switzerland.